南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

伏立诺他在免疫富集型胰腺癌中增强化学免疫治疗

Vorinostat Potentiates Chemoimmunotherapy in Immune-Enriched Pancreatic Cancer

Chen Chen, Dingru Li, Yingna Liao, Zehua Wang, Chunbin Zhu, Zifeng Zhang, Liquan Jin, Yueyue Chen, Jiaoshun Chen, Junyi Xu, Miaoyan Wei, Rong Tang, Xianjun Yu, Si Shi

Journal:Advanced Science

IF:14.1

DOI:10.1002/advs.202521844

PMID:41969226

Published:2026-04-13

research field:分子生物学细胞生物学心脏病学结构生物学泛素-蛋白酶体系统信号转导遗传学与基因组学心脏肥厚生物化学

Abstract

Although pancreatic ductal adenocarcinoma (PDAC) is generally considered an immunologically “cold” tumor, approximately 20% of cases can be classified as immune-hot. However, this immune-enriched (IE) phenotype does not confer a significant survival advantage, highlighting the need to investigate its underlying mechanisms and identify effective therapies. By integrating in vitro drug screening and in silico sensitivity prediction, we identified the HDAC inhibitor vorinostat (SAHA) as a potent sensitizer to chemoimmunotherapy specifically in the IE-PDAC. This effect was validated using T cell-organoid co-cultures and patient-derived xenografts with humanized immune systems. Mechanistically, abundant cytokines (TNF-α, FGF) in the IE tumor microenvironment promote FASN and PARP9 expression. This leads to free fatty acid accumulation and enhanced oxidative phosphorylation, supporting tumor cell survival. SAHA disrupts this “metabolic trap” by concurrently suppressing FASN and PARP9. Single-cell RNA sequencing revealed that the Gemcitabine-SAHA combination remodels the tumor microenvironment by enhancing CD8 + T cell function and depleting cancer-associated fibroblasts. Clinically, we defined a CD8 high /FASN high /PARP9 high signature that identifies an IE patient subgroup with poor survival, representing those most likely to benefit from the “Gemcitabine-Nivolumab-SAHA” triple-combination therapy.

本文使用的Yeasen产品

购物车
客服
转染试用